Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9841927 | 1.00 | CYP2D6 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11402093 | 0.84 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4297866 | 0.84 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL27962069 | 0.84 | CYP2D6 (0.49) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28896711 | 0.79 | SLC1A2 (0.38) | CYP2D6HDAC8SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL11040530 | 0.76 | TSHR (0.49) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL11036091 | 0.76 | TSHR (0.49) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL28008180 | 0.75 | MEN1 (0.47) | CYP2D6SLC7A5SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7296197 | 0.74 | CD69 (0.41) | MEN1CYP2C19KMT2A | |
| SCHEMBL1916264 | 0.74 | PLA2G10 (0.37) | CYP2C9CYP2C19PTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055213-A1 | Endothelin-antagonizing peptide | TANAKA TAKEO (JP) | 2003-03-20 | — | — | US | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-0474273-B1 | A polypeptide capable of interacting with thrombin | ASAHI CHEMICAL IND (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5574007-A | Polypeptide capable of interacting with thrombin | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1996-11-12 | — | — | US | disclosed |
| EP-0679658-A1 | ENDOTHELIN-ANTAGONIZING PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0672680-A1 | NOVEL PEPTIDE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-09-20 | — | — | EP | disclosed |
| EP-0474273-A2 | A polypeptide capable of interacting with thrombin | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4369178-A | Glucosamine peptide derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-01-18 | — | — | US | disclosed |
| EP-0014984-B1 | GLUCOSAMINE-PEPTIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0014984-A1 | Glucosamine-peptide derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-09-03 | — | — | EP | disclosed |
| US-4209441-A | Anti-gastric secretion polypeptide | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4146614-A | TREATMENT OF SCHIZOPHRENIA | STATE OF MICHIGAN (US) | 1979-03-27 | — | — | US | disclosed |
| US-4082736-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4082735-A | NOVEL IMMUNOLOGICAL ADJUVANT COMPOUNDS AND METHODS OF PREPARATION THEREOF | SYNTEX (U.S.A.) INC. (US) | 1978-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055213-A1 | Endothelin-antagonizing peptide | NPY1R, ECE1, EDNRB | CYP2D6 3565/4885HDAC3 2194/4885HDAC1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.